 The BALANCE RCT will randomize critically ill patients with bloodstream infection to 7 versus 14 days of adequate antibiotic treatment; the antibiotic drugs, doses, routes and interval will be left to the discretion of the treating team. Although placebo controls are not feasible, prolonged allocation concealment to day 7 will be used to mitigate selection bias. The primary analysis will assess whether 7 days is associated with non-inferior 90 day survival as compared to 14 days of treatment. Patients from the vanguard BALANCE pilot RCT will be included in the BALANCE main RCT, and participating Canadian sites will continue to enrol patients ultimately 20-25 Canadian sites will be included. BALANCE international collaborators in New Zealand, Australia, Saudi Arabia, the United States, France and Germany are working towards inclusion of sites, to facilitate target sample size recruitment within 5 years. 